Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions

Dr. Abhishek Kanugo; Yash Gandhi

Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions

Abstract

Allergic rhinitis or allergic conditions are associated with the symptoms such as running nose, frequent headache, sore throat, watering of eye, and sometimes coughing as well as eczema also. The delay in the treatment or ignorance may leads to severe health problems like asthma, inability to sleep, severe redness, etc. Bilastine is potent H1 antihistaminic agents used in the therapy of allergic conditions and rhinitis without inducing drowsiness. The current research focused on developing oral thin film of Bilastine for all the allergic conditions. The hydroxypropyl methylcellulose (HPMC) was selected as film former and the physical interaction with Bilastine was confirmed with FTIR. The 3 3 Box-Behnken design was applied in the designing of oral thin film which predicted 17 possible runs in Design of Expert (Version 11). The film former (HPMC E15: X1) plasticizer (PEG 400: X2) and superdisintegrants (CCS: X3) were selected as independent parameters and disintegration time (Y1), folding endurance (Y2) and in-vitro dissolution release (Y3) as dependable parameters in the development of oral thin film. The film was prepared by solvent casting method and evaluated. The optimized batch F10 tested for weight variation, folding endurance (135), disintegration time (12 sec), percentage of dissolution (98.70%) and found stable during accelerated stability studies. The fast-dissolving oral thin film of Bilastine (F10) was developed which showed prompt relief from the allergic conditions.

Keywords

References

[1]. Gómez RM, Croce VH, Zernotti ME, Muiño JC. Active smoking effect in allergic rhinitis. World Allergy Organ J. 2021;14(2):100504. [CrossRef].
[2]. Rosario Filho NA, Satoris RA, Scala WR. Allergic rhinitis aggravated by air pollutants in Latin America: A systematic review. World Allergy Organ J. 2021;14(8):100574. [CrossRef].
[3]. Choi S, Jung MA, Hwang YH, Pyun BJ, Lee JY, Jung DH, et al. Anti-allergic effects of Asarum heterotropoides on an ovalbumin-induced allergic rhinitis murine model. Biomed Pharmacother. 2021;141:111944. [CrossRef].
[4]. Small P, Keith PK, Kim H. Allergic rhinitis. Allergy, Asthma Clin Immunol. 2018;14(2):1–11. [CrossRef].
[5]. Mengi E, Kara CO, Alptürk U, Topuz B. The effect of face mask usage on the allergic rhinitis symptoms in patients with pollen allergy during the covid-19 pandemic. Am J Otolaryngol. 2022;43(1):103206. [CrossRef].
[6]. Okubo K, Suzuki T, Tanaka A, Aoki H. Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial. Allergol Int. 2019;68(2):207–15. [CrossRef].
[7]. Wu TF, Shi WY, Chiu YC, Chan YY. Investigation of the molecular mechanism underlying the inhibitory activities of ethanol extract of Bombyx mori pupa-incubated Cordyceps militaris fruiting bodies toward allergic rhinitis. Biomed Pharmacother. 2021;135:111248. [CrossRef].
[8]. Suryawanshi D, Wavhule P, Shinde U, Kamble M, Amin P. Development, optimization and in-vivo evaluation of cyanocobalamin loaded orodispersible films using hot-melt extrusion technology: A quality by design (QbD)approach. J Drug Deliv Sci Technol. 2021;63:102559. [CrossRef].

[9]. Elbadawi M, Nikjoo D, Gustafsson T, Gaisford S, Basit AW. Pressure-assisted microsyringe 3D printing of oral films based on pullulan and hydroxypropyl methylcellulose. Int J Pharm. 2021;595:120197. [CrossRef].
[10]. Bodini RB, Guimarães J das GL, Monaco-Lourenço CA, Aparecida de Carvalho R. Effect of starch and hydroxypropyl methylcellulose polymers on the properties of orally disintegrating films. J Drug Deliv Sci Technol. 2019;51:403–10. [CrossRef].
[11]. Alaei S, Omidian H. Mucoadhesion and Mechanical Assessment of Oral Films. Eur J Pharm Sci. 2021;159:105727. [CrossRef].
[12]. Takeuchi Y, Nishimatsu T, Tahara K, Takeuchi H. Novel use of insoluble particles as disintegration enhancers for orally disintegrating films. J Drug Deliv Sci Technol. 2019;54:101310. [CrossRef].
[13]. Takeuchi Y, Ikeda N, Tahara K, Takeuchi H. Mechanical characteristics of orally disintegrating films: Comparison of folding endurance and tensile properties. Int J Pharm. 2020;589:119876. [CrossRef].
[14]. Wolthers OD. Bilastine: A new nonsedating oral h1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria. Biomed Res Int. 2013;2013. [CrossRef].
[15]. Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015;13(1). [CrossRef].
[16]. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–83. [CrossRef].
[17]. Zhang L, Mao S. Application of quality by design in the current drug development. Asian J Pharm Sci. 2017;12(1):1–8. [CrossRef].
[18]. Pezik E, Gulsun T, Sahin S, Vural İ. Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. Eur J Pharm Sci. 2021;156:105597. [CrossRef].
[19]. Sharma S, Kanugo A, Gaikwad J. Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach. Mater. Technol. 2021. [CrossRef]
[20]. Prajapati VD, Chaudhari AM, Gandhi AK, Maheriya P. Pullulan based oral thin film formulation of zolmitriptan: Development and optimization using factorial design. Int J Biol Macromol. 2018;107:2075–85. [CrossRef].
[21]. Han X, Yan J, Ren L, Xue M, Yuan Z, Wang T, et al. Preparation and evaluation of orally disintegrating film containing donepezil for Alzheimer disease. J Drug Deliv Sci Technol. 2019;54:101321. [CrossRef].
[22]. Gupta MS, Kumar TP, Gowda DV, Rosenholm JM. Orodispersible films: Conception to quality by design. Adv Drug Deliv Rev. 2021;178:113983. [CrossRef].
[23]. Al-Mogherah AI, Ibrahim MA, Hassan MA. Optimization and evaluation of venlafaxine hydrochloride fast dissolving oral films. Saudi Pharm J. 2020;28(11):1374–82. [CrossRef].
[24]. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67.
[25]. Alhayali A, Vuddanda PR, Velaga S. Silodosin oral films: Development, physico-mechanical properties and in vitro dissolution studies in simulated saliva. J Drug Deliv Sci Technol. 2019;53:101122. [CrossRef].
[26]. Zaki DY, Safwat EM, Nagi SM, Salem HN, Hamdy TM, Moharam LM, et al. A novel dental re-mineralizing blend of hydroxyethyl-cellulose and cellulose nanofibers oral film loaded with nepheline apatite glass: Preparation, characterization and in vitro evaluation of re-mineralizing effect. Carbohydr Polym Technol Appl. 2021;2:100035. [CrossRef].
[27]. Dahmash EZ, Iyire A, Alyami HS. Development of orally dissolving films for pediatric-centric administration of anti-epileptic drug topiramate – A design of experiments (DoE) study. Saudi Pharm J. 2021;29(7):635–47. [CrossRef].
[28]. Zhao Y, Quan P, Fang L. Preparation of an oral thin film containing meclizine hydrochloride: In vitro and in vivoevaluation. Int J Pharm. 2015;496(2):314–22. [CrossRef].
[29]. Bharti K, Mittal P, Mishra B. Formulation and characterization of fast dissolving oral films containing buspirone hydrochloride nanoparticles using design of experiment. J Drug Deliv Sci Technol. 2019;49:420–32. [CrossRef].

Details

Primary Language

English

Subjects

Pharmaceutical Sciences

Journal Section

Research Article

Authors

Dr. Abhishek Kanugo ^*
0000-0002-5205-5906
India

Yash Gandhi
0000-0002-9577-3422
India

Publication Date

June 28, 2025

Submission Date

March 3, 2022

Acceptance Date

May 7, 2022

Published in Issue

Year 2022 Volume: 26 Number: 5

IZ

https://izlik.org/JA74JL68TR

Cite

RIS / Bibtex

APA

Kanugo, D. A., & Gandhi, Y. (2025). Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions. Journal of Research in Pharmacy, 26(5), 1214-1229. https://izlik.org/JA74JL68TR

AMA

1.Kanugo DA, Gandhi Y. Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions. J. Res. Pharm. 2025;26(5):1214-1229. https://izlik.org/JA74JL68TR

Chicago

Kanugo, Dr. Abhishek, and Yash Gandhi. 2025. “Formulation Optimization and Evaluation of Oral Thin Film of Bilastine for the Treatment of Allergic Conditions”. Journal of Research in Pharmacy 26 (5): 1214-29. https://izlik.org/JA74JL68TR.

EndNote

Kanugo DA, Gandhi Y (June 1, 2025) Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions. Journal of Research in Pharmacy 26 5 1214–1229.

IEEE

[1]D. A. Kanugo and Y. Gandhi, “Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions”, J. Res. Pharm., vol. 26, no. 5, pp. 1214–1229, June 2025, [Online]. Available: https://izlik.org/JA74JL68TR

ISNAD

Kanugo, Dr. Abhishek - Gandhi, Yash. “Formulation Optimization and Evaluation of Oral Thin Film of Bilastine for the Treatment of Allergic Conditions”. Journal of Research in Pharmacy 26/5 (June 1, 2025): 1214-1229. https://izlik.org/JA74JL68TR.

JAMA

1.Kanugo DA, Gandhi Y. Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions. J. Res. Pharm. 2025;26:1214–1229.

MLA

Kanugo, Dr. Abhishek, and Yash Gandhi. “Formulation Optimization and Evaluation of Oral Thin Film of Bilastine for the Treatment of Allergic Conditions”. Journal of Research in Pharmacy, vol. 26, no. 5, June 2025, pp. 1214-29, https://izlik.org/JA74JL68TR.

Vancouver

1.Dr. Abhishek Kanugo, Yash Gandhi. Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions. J. Res. Pharm. [Internet]. 2025 Jun. 1;26(5):1214-29. Available from: https://izlik.org/JA74JL68TR